[1]向珍贤 罗素新 黄毕.瓣膜性房颤和非瓣膜性房颤的区别和抗凝策略的差异[J].心血管病学进展,2023,(2):142-145.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.010]
　XIANG ZhenxianLUO SuxinHUANG Bi.The Difference of Definition and Anticoagulation Therapy Strategies Between Valve and Non-valve Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2023,(2):142-145.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.010]
点击复制

瓣膜性房颤和非瓣膜性房颤的区别和抗凝策略的差异()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2023年2期
页码:
142-145
栏目:
综述
出版日期:
2023-02-25

文章信息/Info

Title:
The Difference of Definition and Anticoagulation Therapy Strategies Between Valve and Non-valve Atrial Fibrillation
作者:
向珍贤 罗素新 黄毕
(重庆医科大学附属第一医院心血管内科,重庆 400042)
Author(s):
XIANG ZhenxianLUO SuxinHUANG Bi
(Department of Cardiology,The First Affiliated Hospital of Chongqing Medical UniversityChongqing 400042China)
关键词:
瓣膜性房颤; 非瓣膜性房颤; 抗凝; 华法林; 新型口服抗凝药
Keywords:
Valve atrial fibrillation;  Non-valve atrial fibrillation;  Anticoagulation;  Warfarin;  New oral anticoagulants
DOI:
10.16806/j.cnki.issn.1004-3934.2023.04.010
摘要:
心房颤动（房颤）是临床最常见的心律失常之一，可分为瓣膜性房颤和非瓣膜性房颤，但临床医生常将其混淆。根据目前的指南，瓣膜性房颤是指机械瓣置换术后或二尖瓣中-重度狭窄合并的房颤，其他的均称为非瓣膜性房颤。区别瓣膜性和非瓣膜性房颤是由于其血栓形成的机制和栓塞风险及抗凝策略不同，目前瓣膜性房颤只能使用维生素K拮抗剂（华法林）抗凝，而非瓣膜性房颤可选择华法林或新型口服抗凝药（NOACs），首选NOACs。现就瓣膜性和非瓣膜性房颤定义的演变和药物治疗的循证作一综述，旨在让临床医生对瓣膜性和非瓣膜性房颤的诊治有更好的理解。
Abstract:
Atrail fibrillation is one of the most common arrhythmias in clinical practice and can be divided into valve and non-valve atrial fibrillation; however,clinicians are often confused with the two terminologies. Current guidelines defines valve atrial fibrillation as the post-prosthetic heart valve replacement or moderate to severe mitral stenosis associated atrial fibrillation ,and the others are called non-valve atrial fibrillation. The mechanisms of thrombosis,risk of embolism,and the anticoagulation therapy strategies are distinct between valve and non-valve atrial fibrillation. Current guidelines only recommend vitamin K antagonist (warfarin) for anticoagulation in patients with valve atrial fibrillation,while non-valve atrial fibrillation can adopt warfarin or new oral anticoagulants (NOACs) with the latter as the first choice. This review focuses on the definition evolution of valve and non-valve atrial fibrillation as well as the update of anticoagulation study literatures ,with the aim to provide clinicians with a better understanding of the diagnosis and treatment of valve and non-valve atrial fibrillation

参考文献/References:

[1] Shi S,Tang Y,Zhao Q,et al. Prevalence and risk of atrial fibrillation in China:a national cross-sectional epidemiological study[J]. Lancet Reg Health West Pac,2022,23:100439.

[2] Rivard L,Friberg L,Conen D,et al. Atrial fibrillation and dementia:a report from the AF-SCREEN international collaboration[J]. Circulation,2022,145(5):392-409.

[3] Wolf PA,Abbott RD,Kannel WB. Atrial fibrillation as an independent risk factor for stroke:the Framingham Study[J]. Stroke,1991,22(8):983-988.

[4] Stewart S,Hart CL,Hole DJ,et al. A population-based study of the long-term risks associated with atrial fibrillation:20-year follow-up of the Renfrew/Paisley study[J]. Am J Med,2002,113(5):359-364.

[5] 中华医学会心电生理和起搏分会,中国医师协会心律学专业委员会,中国房颤中心联盟心房颤动防治专家工作委员会. 心房颤动:目前的认识和治疗建议(2021)[J]. 中华心律失常学杂志,2022,26(1):15-88.

[6] Camm AJ,Lip GY,de Caterina R,et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation:an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association[J]. Europace,2012,14(10):1385-1413.

[7] Molteni M,Polo FH,Primitz L,et al. The definition of valvular and non-valvular atrial fibrillation:results of a physicians’ survey[J]. Europace,2014,16(12):1720-1725.

[8] 段俊,王多姿,李娅君,等. 瓣膜性房颤患者的临床特点、卒中一级预防现状及随访调查[J]. 中国现代医学杂志,2018,28(3):119-123.

[9] January CT,Wann LS,Alpert JS,et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society[J]. Circulation,2014,130(23):e199-e267.

[10] 黄从新,张澍,黄德嘉,等. 心房颤动:目前的认识和治疗建议(2018)[J]. 中华心律失常学杂志,2018,22(4):279-346.

[11] January CT,Wann LS,Calkins H,et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society[J]. J Am Coll Cardiol,2019, 74(1):104-132.

[12] Hindricks G,Potpara T,Dagres N,et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS):The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC[J]. Eur Heart J,2021,42(5):373-498.

[13] Jang AY,Seo J,Park YM,et al. ABO Blood Type Is Associated with Thrombotic Risk in Patients with Nonvalvular Atrial Fibrillation[J]. J Clin Med,2022,11(11):3064.

[14] Samaras A,Vrana E,Kartas A,et al. Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation[J]. BMC Cardiovasc Disord,2021,21(1):453.

[15] Chiang CE,Chao TF,Choi EK,et al. Stroke prevention in atrial fibrillation:a scientific statement of JACC:Asia (Part 1)[J]. JACC Asia,2022,2(4):395-411.

[16] 韩志杰,段红霞,张文治,等. 不同性别老年非瓣膜性心房颤动患者的临床特点[J]. 中华老年心脑血管病杂志,2021,23(8):823-827.

[17] 刘佳琦,魏猛,迪拉热·太外库力,等. 非瓣膜性心房颤动患者左心耳功能异常与血栓形成事件的相关性研究[J]. 中华内科杂志,2022,61(8):921-927.

[18] 段园霞,潘志刚,顾杰,等. 社区老年非瓣膜性心房颤动患者抗凝治疗现状及影响因素研究[J]. 中国全科医学,2022,25(25):3114-3121.

[19] Wolf PA,Dawber TR,Thomas HJ,et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke:the Framingham study[J]. Neurology,1978,28(10):973-977.

[20] de Caterina R,Camm AJ. What is ’valvular’ atrial fibrillation? A reappraisal[J]. Eur Heart J,2014,35(47):3328-3335.

[21] Fauchier L,Philippart R,Clementy N,et al. How to define valvular atrial fibrillation?[J]. Arch Cardiovasc Dis,2015,108(10):530-539.

[22] Hart RG,Pearce LA,Aguilar MI. Meta-analysis:antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation[J]. Ann Intern Med,2007,146(12):857-867.

[23] Ruff CT,Giugliano RP,Braunwald E,et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation:a meta-analysis of randomised trials[J]. Lancet,2014,383(9921):955-962.

[24] Du X,Guo L,Xia S,et al. Atrial fibrillation prevalence,awareness and management in a nationwide survey of adults in China[J]. Heart,2021,107(7):535-541.

[25] 胡志成,蒋超,郑黎晖,等. 2019年中国心房颤动医疗质量控制报告[J].中国循环杂志,2020,35(5):427-437.

[26] Kim JY,Kim SH,Myong JP,et al. Outcomes of direct oral anticoagulants in patients with mitral stenosis[J]. J Am Coll Cardiol,2019,73(10):1123-1131.

[27] Dawwas GK,Dietrich E,Cuker A,et al. Effectiveness and safety of direct oral anticoagulants versus warfarin in patients with valvular atrial fibrillation:a population-based cohort study[J]. Ann Intern Med,2021,174(7):910-919.

[28] Connolly SJ,Karthikeyan G,Ntsekhe M,et al. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation[J]. N Engl J Med,2022,387(11):978-988..

[29] Dawwas GK,Cuker A,Barnes GD,et al. Apixaban versus rivaroxaban in patients with atrial fibrillation and valvular heart disease:a population-based study[J]. Ann Intern Med,2022,175(11):1506-1514.

[30] Eikelboom JW,Connolly SJ,Brueckmann M,et al. Dabigatran versus warfarin in patients with mechanical heart valves[J]. N Engl J Med,2013,369(13):1206-1214.

[31] Malik AH,Yandrapalli S,Aronow WS,et al. Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves[J]. Heart,2019,105(18):1432-1436.

[32] Guimaraes HP,Lopes RD,de Barros E SP,et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve[J]. N Engl J Med,2020,383(22):2117-2126.

[33] Steffel J,Verhamme P,Potpara TS,et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation[J]. Eur Heart J,2018,39(16):1330-1393.

相似文献/References:

[1]林莹 徐勇郭新红 刘昱圻.具有不同肌酐清除率水平的中国高龄非瓣膜性心房颤动患者应用利伐沙班的剂量选择研究[J].心血管病学进展,2019,(8):1176.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.027]
　LIN Ying,XU Yong,GUO Xinhong,et al.Dose Selection of Rivaroxaban for Elderly Patients of Non-valvular Atrial Fibrillation with Different Levels of Creatinine Clearance in China[J].Advances in Cardiovascular Diseases,2019,(2):1176.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.027]

更新日期/Last Update: 2023-03-23